Read the full paper in Brain Communications: academic.oup.com/braincomms/advance-article/doi/10.1093/braincomms/fcae162/7680229
The dynamic phase of preclinical Alzheimer’s disease, as characterised by accumulating cortical amyloid-β (Aβ), is a window of opportunity for Aβ lowering therapies to have greater efficacy. Biomarkers that accurately predict Aβ accumulation may be of critical importance for participant inclusion in secondary prevention trials and thus enhance development of early Alzheimer’s disease therapies. We compared the ability of baseline plasma phosphorylated tau at threonine181 (pTau181), pTau217 and Aβ-PET load to predict future Aβ accumulation in asymptomatic elderly.
28 май 2024
